Alector (ALEC) Income towards Parent Company (2018 - 2026)
Alector (ALEC) reported Income towards Parent Company of -$22.9 million for Q1 2026, up 43.34% year-over-year from -$16.0 million in Q1 2025, and up 38.47% quarter-over-quarter from -$37.3 million in Q4 2025.
Alector (ALEC) Income towards Parent Company (2018 - 2026) Analysis & Trends
Alector (ALEC) has 9 years of Income towards Parent Company data on file, last reported at -$22.9 million in Q1 2026.
- Income towards Parent Company for Q1 2026 came in at -$22.9 million, up 43.34% year-over-year; the trailing twelve-month figure through Mar 2026 was -$125.4 million (down 1.68% YoY), and the FY2025 annual result was -$142.9 million, down 20.19% from the prior year.
- Income towards Parent Company climbed to -$22.9 million in Q1 2026 per ALEC's latest filing, from -$37.3 million in the prior quarter.
- Over five years, Income towards Parent Company peaked at $9.9 million in Q2 2022 and troughed at -$51.4 million in Q4 2022.
- A 5-year average of -$32.1 million and a median of -$38.7 million in 2024 frame the typical range for Income towards Parent Company.
- The sharpest annual moves came in 2022 and 2024: Income towards Parent Company soared 117.92% in 2022, then tumbled 2912.8% in 2024.
- A 5-year view of Income towards Parent Company shows it stood at -$51.4 million in 2022, then gained by 21.37% to -$40.4 million in 2023, then jumped by 95.18% to -$1.9 million in 2024, then tumbled by 1815.06% to -$37.3 million in 2025, then surged by 38.47% to -$22.9 million in 2026.
- Business Quant data shows ALEC's Income towards Parent Company at -$22.9 million in Q1 2026, -$37.3 million in Q4 2025, and -$34.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Alector | 193.53 Mn | -12.98 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.93 Mn |
| Dec 31, 2025 | -37.27 Mn |
| Sep 30, 2025 | -34.67 Mn |
| Jun 30, 2025 | -30.52 Mn |
| Mar 31, 2025 | -40.47 Mn |
| Dec 31, 2024 | -1.95 Mn |
| Sep 30, 2024 | -42.22 Mn |
| Jun 30, 2024 | -38.68 Mn |
| Mar 31, 2024 | -36.08 Mn |
| Dec 31, 2023 | -40.40 Mn |
| Sep 30, 2023 | -44.48 Mn |
| Jun 30, 2023 | 1.38 Mn |
| Mar 31, 2023 | -45.86 Mn |
| Dec 31, 2022 | -51.38 Mn |
| Sep 30, 2022 | -46.15 Mn |
| Jun 30, 2022 | 9.88 Mn |
| Mar 31, 2022 | -44.62 Mn |
| Dec 31, 2021 | -55.61 Mn |
| Sep 30, 2021 | 126.60 Mn |
| Jun 30, 2021 | -55.15 Mn |